BRCA 1 and 2 - The Breast Cancer Genes
BRCA 1 and 2 represent just one of the 9 pathways [https://www.flemingmethod.com/answers] I have explained as possible cancer pathways for people following either infection with the SARS-CoV-2 (COVID) viruses or the presentation of the spike protein following vaccination.
​
While the following graphic may look like an example of Where's Waldo, you will see the BRCA 1 & 2 connection in the gold colored square.
Many people have heard of these two genes, known for their associated with Breast Cancer. These genes known as Breast Cancer 1 and 2 (BRCA 1 & 2) were discovered when a group of women in Southwestern Iowa who were genetically related (families) were diagnosed with breast cancer.
​
The hunt for a possible genetic link to these breast cancer was accomplished through the work of many, including my friend and colleague Dr. Henry Lynch.
Dr. Lynch - who became my friend and colleague - like too many of those who participated in my medical education passed away from cancer.
​
The BRCA 1 and 2 genes are critical for repairing DNA damage, as shown in the slide below, resulting from a variety of DNA insults, some of which are discussed in more detail in the link to my other website shown above.
BRCA 1 and 2 is considered one of a few known tumor suppressor genes, whose activation stops cellular activity and division, preventing development and spread of the cancer. The others shown here include p53 - a gene that produces a protein essential for regulation of cell growth, and the adenomatous polyposis coli (APC) gene that produces a protein critical in regulating cell proliferation - noted for its role in colorectal cancers.
Thanks to Dr. Lynch's work and others, BRCA 1 and 2 genes are well known for their role in potentiating the development of breast cancer, when the genes malfunction.
​
However, BRCA 1 and 2, I have argued, should more properly be thought of as hormonally mediated genes; since their dysfunction is associated with breast, uterine, ovarian and prostate cancers.
​
In addition, dysfunction of BRCA 1 and 2 is associated with a variety of other cancers frequently not discussed; but, known about as shown in the next slide.
As someone who personally knew Henry, I can assure you that it frustrated him that women would undergo prophylactic mastectomies in an effort to, as they see it, avoid the development of breast cancer.
​
While it is true that having abnormal BRCA 1 and/or 2 genes is associated with a 25% increased risk of developing breast cancer - along with other cancers - this risk occurs in the face of other factors which can help promote the development of breast cancer. One of those contributing factors is a high fat diet.
​​
While it is understandable, given the failures of mammography and other qualitative or anatomic imaging - prior to the development of FMTVDM - that women with the BRCA 1 and 2 gene abnormalities, would be afraid that they could not rely upon mammography to exclude their risk of breast cancer; as the following schematic demonstrates, breast tissue extends from the muscles in the chest wall to the skin itself.
A simple mastectomy, thought of by many people as simply removing breast tissue under the skin, may not remove all of the breast tissue, leaving residual breast tissue behind, increasing the potential risk for metastasis (spread) should a breast cancer develop in remaining tissue, with less breast tissue through which the developing cancer must traverse before reaching the chest wall, where metastasis is greater.
​
To reduce the risk of breast cancer would require the complete removal of breast, skin, nipple, lymph nodes (where a cancer might already have spread to, or at least cancer cells), and potentially the chest wall muscles (where breast cancer cells might have penetrated).
​
None of which reduces the associated risk of ovarian, uterine, or if male - prostate, cancers.
​
If this discussion leaves you with a sense of dismay, consider the women who have been told they have the BRCA 1 and/or 2 risk of breast cancer.
​
Understanding the limitations of mammography and the risk of developing breast cancer, what would you do?
​
As we have discussed previously, cancer is the result of normal tissue transitioning through a series of InflammoThrombotic Immunologic Response (ITIR) changes into the ITIR Disease (ITIRD) known as cancer. The inability of qualitative imaging tests like mammography to distinguish these transitional changes has resulted in many women and men being left with the hard and sometimes fast decision of what to do with a diagnosis of abnormal BRCA 1 and/or 2 genes.
In the face of uncertainty resulting from diagnostic limitations - sensitivity & specific errors - it is easy for people to make decisions out of fear of the unknown. Such may easily be the case for women and men with a genetic predisposing for cancer.
​
For many people who learn they have a breast cancer gene (BRCA) - either 1 (BRCA1) or 2 (BRCA2) - their fear is real. The fear of dying from a disease they do not yet have, but which they also do not have a dependable way of knowing when or if they might develop it. The fear of not having the ability to detect breast cancer changes leading up to cancer.
​
As actress Angelina Jolie so bravely shared with people, the fear and risks are very real. They are not a hypothetical in some medical textbook.
Many people, like Angelina Jolie, elect to undergo bilateral prophylactic mastectomy in the hope of preventing the development of breast cancer; although as you will see, she was also told about her increased risk of ovarian cancer.
Failure of the Medical System
​
A decision by so many people, to have part of their body removed out of fear that they may develop cancer, and a fear that the cancer could develop without being detected by the limited diagnostic approach being used by the medical system must be recognized as a loss of confidence in medicine itself.
​
Having said that, this failure need no longer continue.
The following quantitative FMTVDM measurements show the results of a woman who was told there was nothing wrong with her mammogram.
​
By contrast, the measured outcomes of FMTVDM demonstrated - confirmed by needle biopsy - that this woman actually had early breast cancer, known as Ductal Carcinoma In-Situ (DCIS), or breast cancer within the milk ducts of her breast. A cancer that had not yet moved beyond the milk duct. An easily treatable cancer, yet one missed by mammography.
​
Is it any wonder that people like Angelina Jolie have opted for the voluntary removal of both breasts given the limitations of qualitative imaging like mammography.
​
Quantification with FMTVDM is clearly the type of diagnostic information that would be incredibly valuable for any patient, particularly one with breast cancer genes or dense breasts.
​
Finally, I leave you with an example of FMTVDM imaging done for a woman with BRCA1 & BRAC2. She was referred for FMTVDM imaging by Dr. Henry Lynch in March of 2001. Both breasts had FMTVDM measurements in the normal range - she decided not to undergo bilateral prophylactic mastectomy.
